Clinical relevance of serum procalcitonin in patients with aneurysmal subarachnoid hemorrhage
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김호중 | - |
dc.contributor.author | 이호준 | - |
dc.contributor.author | Kim, Bum-Tae | - |
dc.contributor.author | Shin, Dong-Seong | - |
dc.date.accessioned | 2022-11-29T05:41:05Z | - |
dc.date.available | 2022-11-29T05:41:05Z | - |
dc.date.issued | 2022-11 | - |
dc.identifier.issn | 1792-0981 | - |
dc.identifier.issn | 1792-1015 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/21762 | - |
dc.description.abstract | Cerebral vasospasm (CV), which is closely related to the prognosis of aneurysmal subarachnoid hemorrhage (aSAH), is known to be related to an inflammatory reaction. The aim of the present study was to investigate predictable values of procalcitonin (PCT) for systemic infection and the development of CV in patients with aSAH. Patients who underwent endovascular treatment for aSAH were retrospectively enrolled. Receiver operating characteristic curve analysis was performed to evaluate the predicable value of PCT for systemic infection and CV in patients with aSAH. To clarify the association of PCT and CV, additional subgroup analysis was performed for patients without systemic infection. Multivariate logistic regression was used to explore the associations of PCT and the development of CV. A total of 374 patients with aSAH were enrolled. Of them, 164 (43.9%) had systemic infection. Optimal cutoff value of PCT for systemic infection was 0.21 ng/ml (P<0.001). In subgroup analysis of 210 patients without infection, 0.09 ng/ml of PCT level was defined as the optimal cutoff value for predicting CV after aSAH (P<0.001). In multivariate logistic regression analysis, PCT was a significant predicting factor for CV (odds ratio, 1.82; 95% confidence interval, 1.42-2.96; P=0.015). Overall, PCT had predictable value for systemic infection and the development of CV in patients who underwent endovascular treatment for aSAH. Further studies are needed to validate our results and establish its clinical applicability. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Spandidos Publications | - |
dc.title | Clinical relevance of serum procalcitonin in patients with aneurysmal subarachnoid hemorrhage | - |
dc.type | Article | - |
dc.publisher.location | 그리이스 | - |
dc.identifier.doi | 10.3892/etm.2022.11590 | - |
dc.identifier.wosid | 000864498400001 | - |
dc.identifier.bibliographicCitation | Experimental and Therapeutic Medicine, v.24, no.5 | - |
dc.citation.title | Experimental and Therapeutic Medicine | - |
dc.citation.volume | 24 | - |
dc.citation.number | 5 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | DELAYED CEREBRAL-ISCHEMIA | - |
dc.subject.keywordPlus | C-REACTIVE PROTEIN | - |
dc.subject.keywordPlus | SEPSIS | - |
dc.subject.keywordPlus | ASSOCIATION | - |
dc.subject.keywordPlus | PREDICTOR | - |
dc.subject.keywordPlus | UTILITY | - |
dc.subject.keywordAuthor | aneurysm | - |
dc.subject.keywordAuthor | delayed cerebral ischemia | - |
dc.subject.keywordAuthor | procalcitonin | - |
dc.subject.keywordAuthor | subarachnoid hemorrhage | - |
dc.subject.keywordAuthor | vasospasm | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.